Primaa, a Paris, France-based developer of AI software for automated and accurate histological and cancer diagnostics, has extended its financing round to €7 million.
Investors
The round was backed by the partnership fund between MH Innov’ and Elaia, and SWEN Capital Partners, with additional participation from Super Capital and members of the Wendel family.
Primaa Use of Funds
The company will use the funding to strengthen its sales organization, accelerate its European rollout and customer support, develop new predictive AI models, and prepare for U.S. expansion through FDA certification activities.
About Primaa
Founded in 2018, Primaa is a medtech company that develops AI software for automated and accurate cancer diagnosis, specifically designed to empower pathologists. The platform utilizes deep learning and image analysis technology to quickly and accurately detect cancer biomarkers. Headquartered in Paris, France, Primaa’s tools are already deployed at French institutions including Institut Curie, AP-HP, and Saint-Joseph Hospital, with early European rollouts at ZAS Laboratory and Liège University Hospital.
Funding Details
Company: Primaa SAS
Raised: €7.0M
Round: Unknown
Funding Date: November 2025
Investors: MH Innov’, Elaia, SWEN Capital Partners, Super Capital, Wendel family members
Company Website: https://www.primaa.ai/
Software Category: HealthTech / AI Diagnostics / Digital Pathology
Source: https://tech.eu/2025/10/29/primaa-raises-eur7m-to-accelerate-product-growth-and-international-expansion/